Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvage Radiotherapy vs Enzalutamide for High-risk Biochemical Recurrence or PSA Persistence after Radical Prostatectomy
KCT0012360Phase 4Not yet recruiting
- Sponsor
- Chung-Ang University Hospital
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Chung-Ang University Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on KCT0012360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012360.